ABSTRACT
The wave of individuals impacted by dementia continues to rise rapidly as worldwide lifespan increases. Dietary strategies to slow cognitive decline and prolong time to clinical dementia remain understudied, but with potentially powerful public health consequences. Indeed, previously conducted large, randomized, placebo-controlled trials of micronutrients remain an under-leveraged resource to study changes in cognitive performance. As a motivating example, we highlight an ancillary report from the Physicians' Health Study, where subjects randomized to ß-carotene (a provitamin A carotenoid) had a more attenuated change in longitudinal global cognitive performance and verbal memory, as compared to subjects randomized to placebo. Despite mechanistic evidence from cell and animal studies supporting a vitamin A-mediated role in the biology associated with cognition, limited follow-up work has been conducted. We argue that dietary factors (including provitamin A) deserve a second look, leveraging multi-omic approaches, to elucidate how they may mitigate cognitive decline and dementia risk.
Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Dementia , Humans , beta Carotene/therapeutic use , Provitamins/therapeutic use , Cognitive Dysfunction/drug therapy , Cognition , Alzheimer Disease/drug therapyABSTRACT
The efficacy of ß-cryptoxanthin (BCX), a high-protein diet (HPD), or both in reducing oxidative stress and inflammation in nonalcoholic fatty liver disease (NAFLD) has never been examined within a randomized controlled trial (RCT). Thus, we aimed to assess the efficacy of an energy-restricted HPD supplemented with BCX in alleviating these conditions in NAFLD in an RCT design. We hypothesized that this combination may improve oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet. Ninety-two ultrasonographically confirmed overweight/obese adult NAFLD patients attending an outpatient clinic in Ahvaz, Iran, were recruited for this 12-week, single-center, parallel-group, double-blind RCT from 2017 to 2018. Subjects were randomized into 4 equal groups (nâ¯=â¯23): HPD-BCX (energy-restricted HPDâ¯+â¯BCX), HPD (energy-restricted HPDâ¯+â¯placebo), BCX (standard energy-restricted diet + BCX), and control (standard energy-restricted diet + placebo). Serum levels of oxidative stress- and inflammation-related markers, as primary outcome measures, were determined at baseline and at the study end point. The 1-way analysis of covariance models in the intention-to-treat population (Nâ¯=â¯92) showed that the HPD-BCX group achieved greater 12-week reductions in malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, and total cytokeratin-18 (CK18-M65) but higher increases in total antioxidant capacity and adiponectin compared to the control group (mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9â¯nmol/mL, -1.0â¯mg/L, -2.0â¯ng/L, -270.9â¯ng/L, 2.5â¯U/mL, and 1.9â¯mg/L, respectively; all Pâ¯<â¯.001). These results show that an energy-restricted HPD supplemented with BCX more efficaciously alleviates oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet.
Subject(s)
Beta-Cryptoxanthin/therapeutic use , Caloric Restriction/methods , Diet, High-Protein/methods , Inflammation/therapy , Non-alcoholic Fatty Liver Disease/therapy , Oxidative Stress/drug effects , Adult , Beta-Cryptoxanthin/blood , Biomarkers/blood , Combined Modality Therapy/methods , Dietary Supplements , Double-Blind Method , Female , Humans , Inflammation/diet therapy , Inflammation/drug therapy , Iran , Male , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/diet therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Provitamins/blood , Provitamins/therapeutic use , Treatment OutcomeABSTRACT
Nicotinamide riboside (NR) is a newly discovered nicotinamide adenine dinucleotide (NAD+) precursor vitamin. A crystal form of NR chloride termed NIAGEN is generally recognized as safe (GRAS) for use in foods and the subject of two New Dietary Ingredient Notifications for use in dietary supplements. To evaluate the kinetics and dose-dependency of NR oral availability and safety in overweight, but otherwise healthy men and women, an 8-week randomized, double-blind, placebo-controlled clinical trial was conducted. Consumption of 100, 300 and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ (i.e., 22%, 51% and 142%) and other NAD+ metabolites within 2 weeks. The increases were maintained throughout the remainder of the study. There were no reports of flushing and no significant differences in adverse events between the NR and placebo-treated groups or between groups at different NR doses. NR also did not elevate low density lipoprotein cholesterol or dysregulate 1-carbon metabolism. Together these data support the development of a tolerable upper intake limit for NR based on human data.
Subject(s)
Dietary Supplements , Niacinamide/analogs & derivatives , Overweight/diet therapy , Provitamins/adverse effects , Provitamins/therapeutic use , Administration, Oral , Adult , Double-Blind Method , Female , Healthy Volunteers , Humans , Male , Middle Aged , NAD/blood , NAD/urine , Niacinamide/administration & dosage , Niacinamide/adverse effects , Niacinamide/metabolism , Niacinamide/therapeutic use , Overweight/blood , Overweight/urine , Provitamins/administration & dosage , Provitamins/metabolism , Pyridinium Compounds , Treatment OutcomeABSTRACT
The porphyrias are a group of rare metabolic disorders that result from defects in heme biosynthesis. Erythropoietic protoporphyria (EPP) is the most common inherited porphyria in children and is diagnosed in most individuals after the onset of cutaneous manifestations. Hepatobiliary disease affects the minority of individuals with EPP and usually manifests in patients with an established diagnosis of EPP. We report on a classic but rare case of EPP that masqueraded as cholestasis. An 8-year-old boy was referred to the Hepatology Clinic after an abrupt onset of jaundice with a longstanding history of dermatitis. The diagnosis of EPP was established with liver biopsy, which revealed dense, dark-brown pigment in hepatocytes and Kupffer cells that, on polarization, displayed bright-red birefringence and centrally located Maltese crosses. Plasma total porphyrins and erythrocyte protoporphyrin were elevated and confirmed a diagnosis of EPP. We hope to raise awareness of this diagnosis among pediatricians, hepatologists, and pathologists and increase the consideration of EPP in patients with cholestatic liver disease and chronic dermatitis.
Subject(s)
Cholestasis/diagnosis , Protoporphyria, Erythropoietic/diagnosis , Child , Cholagogues and Choleretics/therapeutic use , Cholestyramine Resin/therapeutic use , Chronic Disease , Diagnosis, Differential , Humans , Male , Photosensitivity Disorders/drug therapy , Photosensitivity Disorders/etiology , Protoporphyria, Erythropoietic/complications , Protoporphyria, Erythropoietic/drug therapy , Provitamins/therapeutic use , Pruritus/etiology , Ursodeoxycholic Acid/therapeutic use , beta Carotene/therapeutic useSubject(s)
Blood Proteins/metabolism , Favism/drug therapy , Testis/drug effects , Vicia faba/adverse effects , beta Carotene/therapeutic use , Animals , Blood Cells/drug effects , Glucosephosphate Dehydrogenase Deficiency/complications , Glucosephosphate Dehydrogenase Deficiency/drug therapy , Male , Provitamins/pharmacology , Provitamins/therapeutic use , Rats, Sprague-Dawley , beta Carotene/pharmacologyABSTRACT
The systematic review and meta-analysis of published randomised controlled trials (RCTs) was conducted to review the effectiveness of current chemopreventive agents in the treatment of oral leukoplakia lesions (OPLs) and prevention of their progression to oral cancer. Material was identified through a retrospective literature search of the electronic PubMed database, Embase and Cochrane Library between 2008 and 2016.Eight RCTs were included for systematic review. The pooled estimate showed a 14% greater chance of responding for those randomised to interventions compared with placebo (Risk Ratio [RR] 1.14, 95% confidence interval [CI] 0.72 to 1.81). The CI from individual studies overlapped. The results suggested that there were no significant differences in comparing clinical responses between chemopreventive agents with placebo in treatment of OPLs. It is time to investigate new agents for oral cancer chemoprevention.
Subject(s)
Antineoplastic Agents/therapeutic use , Leukoplakia, Oral/drug therapy , Mouth Neoplasms/prevention & control , Precancerous Conditions/drug therapy , Chemoprevention , Erlotinib Hydrochloride/therapeutic use , Humans , Isotretinoin/therapeutic use , Provitamins/therapeutic use , Tea , Treatment Outcome , Vitamin A/therapeutic use , Vitamins/therapeutic use , beta Carotene/therapeutic useABSTRACT
BACKGROUND: Vitamin A deficiency remains a nutritional concern in sub-Saharan Africa. Conventionally bred maize hybrids with high provitamin A carotenoid concentrations may have the potential to improve vitamin A status in maize-consuming populations. OBJECTIVE: We evaluated the efficacy of regular provitamin A carotenoid-biofortified "orange" maizemeal (â¼15 µg ß-carotene/g) consumption in improving vitamin A status and reducing vitamin A deficiency in children. DESIGN: This was a cluster-randomized controlled trial in the rural farming district of Mkushi, Zambia. All 4- to 8-y-old children in an â¼400-km(2) area were identified and grouped by proximity into clusters of â¼15-25 children. We randomly assigned clusters to 1) orange maizemeal (n = 25), 2) white maizemeal (n = 25), or 3) a parallel, nonintervention group (n = 14). Children in intervention clusters (n = 1024) received 200 g maizemeal for 6 d/wk over 6 mo; the maizemeal was prepared according to standardized recipes and served in cluster-level kitchens. Staff recorded attendance and leftovers. We collected venous blood before and after the intervention to measure serum retinol, ß-carotene, C-reactive protein, and α1-acid glycoprotein. RESULTS: Intervention groups were comparable at baseline, and vitamin A status was better than anticipated (12.1% deficient on the basis of serum retinol <0.7 µmol/L). Although attendance at meals did not differ (85%), median daily maize intake was higher in white (154 g/d) than in orange (142 g/d) maizemeal clusters. At follow-up, mean serum ß-carotene was 0.14 µmol/L (95% CI: 0.09, 0.20 µmol/L) higher in orange maizemeal clusters (P < 0.001), but mean serum retinol (1.00 ± 0.33 µmol/L overall) and deficiency prevalence (17.1% overall) did not differ between arms. CONCLUSION: In this marginally nourished population, regular biofortified maizemeal consumption increased serum ß-carotene concentrations but did not improve serum retinol. This trial was registered at clinicaltrials.gov as NCT01695148.
Subject(s)
Diet , Edible Grain , Food, Fortified , Provitamins/pharmacology , Vitamin A/blood , Zea mays , beta Carotene/pharmacology , C-Reactive Protein/metabolism , Child , Child, Preschool , Female , Humans , Male , Nutritional Status , Provitamins/blood , Provitamins/therapeutic use , Rural Population , Treatment Outcome , Vitamin A Deficiency/blood , Vitamin A Deficiency/diet therapy , Vitamin A Deficiency/drug therapy , Zambia , beta Carotene/blood , beta Carotene/therapeutic useABSTRACT
Various creams are available for superficial second-degree burns (SSDB) of the face. We evaluated provitamin pantothenic acid versus ß-glucan for SSDB of the face using the O2C laser Doppler system and digital photo analysis. Out of 20 patients (January to December 2012) with facial burns, 7 with SSDB of both cheeks were included to our study. Burned cheek wounds were treated using pantothenic acid or ß-glucan. Digital photos of marked regions were taken daily from predefined distances. Microcirculation was measured at marked regions for 7 days at scheduled time points using the O2C laser Doppler. Data were evaluated using the SPSS program (SPSS Inc., Chicago, IL). Wounds treated with ß-glucan showed faster reepithelialization. O2C laser Doppler measurements showed faster increase in SO2, microvascular perfusion, hemoglobin content, and blood flow. This correlated good with clinical Vancouver Scar Scale results. Although not statistically significant, ß-glucan cream therapy of SSDB results in aesthetically superior outcome and faster reepithelialization.